## **REMARKS**

Applicant's undersigned representative thanks Drs. Marvich and Nguyen for the courtesy extended during the Office interview on December 9, 2005.

The above claim amendments reflect the agreement reached during the interview, which amendments should overcome all outstanding claim rejections and place all claims in condition for allowance, with the exception of the provisional double-patenting rejection. Specifically, the amendments to the claims emphasize that the claimed methods are for inhibiting the growth of cancerous cells and that the vector expressing a cytochrome P450 enzyme is administered directly to the cancerous cells.

Applicant wishes to note for the record that during the interview, the issue of "direct administration" was explicitly discussed, and the Examiners and the undersigned agreed that for the claimed method, direct administration encompasses more than intra-tumor (i.t.) injection of the expression vector and includes, for example, intraperitoneal administration, ex vivo cell transfection, and i.v. administration especially in the case of leukemia.

Applicant further submits concurrently herewith a suitable Terminal Disclaimer which should overcome the provisional double-patenting rejection.

If there are any questions regarding the present application, please contact the undersigned at 202-624-2500.

Pursuant to 37 C.F.R. §1.136(a), Applicant hereby requests a one-month extension of time in which to file this paper. Authorization for payment of the one-month extension fee is attached. If in error, the Commissioner is hereby

authorized to charge any prescribed fees not otherwise provided for to Deposit Account No. 05-1323, referencing Attorney Docket No. 010331.49927US).

Respectfully submitted,

December 22, 2005

Kening La, Ph.D.

Registration No. 44,872

J. D. Evans

Registration No. 26,269

CROWELL & MORING, LLP Intellectual Property Group P.O. Box 14300 Washington, DC 20044-4300 (202) 624-2500 (telephone) (202) 628-8844 (telecopier) JDE:KLI:rk:2688140